Thyme Care raises $125M+ as Robin Shah builds an oncology parent company

Why it matters

Thyme Care has put its existing oncology-navigation operation under a parent company that plans to build independent businesses around biosimilar adoption and clinical-trial enrollment. The structure gives Robin Shah a vehicle to apply six years of oncology relationships and operating experience to narrower problems beyond navigation.

Nashville-based Thyme Care announced on September 2 that it raised more than $125 million at a valuation above $2 billion. Co-founders Robin Shah and Bobby Green, M.D. are also placing the six-year-old oncology-navigation company under a new parent organization designed to build additional cancer-care businesses.

Morgan Health led the Series E, joined by Humana, CVS Health Ventures, AlleyCorp, HealthQuest Capital and other investors named in the announcement. Thyme Care's September 2025 Series D announcement said the $97 million round brought total funding to $275 million. The latest financing takes implied cumulative capital above $400 million, although Thyme Care has not disclosed a revised total.

The consequential piece of the announcement is Thyme Companies, a new parent organization that will own Thyme Care and develop independent businesses aimed at specific bottlenecks in cancer care. Thyme Companies has identified two initial workstreams: increasing adoption of lower-cost biosimilar drugs and enrolling more patients in clinical trials. The first additional business is expected to launch later in 2026.

Shah will serve as executive chairman of Thyme Companies and lead development of those businesses with Green, Thyme Care's president and chief medical officer. Brad Diephuis, who became Thyme Care's CEO effective September 1, will continue running the core operation. Thyme Care's brand, partnerships and member experience are staying in place.

The founder's second act

Shah's oncology career began in his father's community cancer practice in Gettysburg, Pennsylvania. After earning a biomedical engineering degree at George Washington University, he spent about five years as the practice administrator and business manager, helping his father contend with financial pressure and competition from hospital systems. He later earned an MBA in Medical Services Management from Johns Hopkins University's Carey Business School.

Shah later worked at Flatiron Health and was a founding member of OneOncology, where he served as chief commercial officer, before starting Thyme Care with Green in 2020. Shah has tied Thyme Care's origins to the fragmentation and patient-access problems he saw inside his father's practice.

Green brought the clinical side of the partnership. He practiced as a medical oncologist for 17 years in West Palm Beach, Florida, and was a managing partner at Palm Beach Cancer Institute. He later served as chief medical officer at Cancer Clinics of Excellence and held senior clinical leadership roles at Flatiron Health, working on oncology software, clinical content and clinical-trial infrastructure.

The pair initially focused Thyme Care on problems that appear between medical appointments: finding specialists, coordinating visits, triaging symptoms, arranging transportation and helping patients understand insurance and financial assistance. Thyme Care describes a set of products supporting that work: Thyme Care Connect handles member messaging, symptom check-ins and care goals; Thyme Care Signal provides eligibility, activity and navigation information to providers; and Thyme Box is its care-management and analytics platform.

Thyme Companies gives Shah's broader oncology plans a formal home outside the operating structure Diephuis now leads. The leadership handoff was the preparatory move. Thyme Care said in July that Shah would leave the CEO role to pursue new businesses involving drug affordability, clinical trials and care coordination. Under the resulting division of responsibilities, Diephuis runs Thyme Care while Shah develops the new parent company's businesses.

Payer money for payer problems

The investor group is more instructive than the headline valuation. Morgan Health invests on behalf of JPMorganChase's employer-health strategy. Humana and CVS Health operate across insurance and care delivery. Those businesses give the investors a view into oncology spending and drug costs, although Thyme Care has not described how that experience will shape the new ventures.

The investor mix could help Thyme Companies reach large healthcare buyers, although Thyme Care has not described any resulting commercial agreements. The additional businesses will need to demonstrate savings, access or clinical value that health plans and employers can measure.

Biosimilars are a logical first target. The Food and Drug Administration describes biosimilars as highly similar to approved biologic medicines, with no clinically meaningful differences in safety or effectiveness. Their adoption can reduce drug spending, but prescribing decisions, insurance coverage, supply and coordination among oncologists, pharmacies and health plans all affect use.

Thyme Care says its model is delivered in partnership with oncologists, health plans, employers and primary-care groups. On its provider page, the company says it contracts with payers, partners with oncology practices, shares savings with provider partners and takes full downside risk in certain performance programs.

Clinical-trial enrollment presents a separate coordination problem. The National Cancer Institute's enrollment guidance describes a process that requires patients and care teams to identify studies, review eligibility and contact research sites. Thyme Companies has not disclosed the product, customers or revenue model for its planned clinical-trial business.

A crowded oncology market

Thyme Care is competing with companies that approach cancer navigation and spending from different parts of the healthcare system. Its main distinction is a combination of human navigation, payer and provider integration, and financial accountability through value-based contracts. Thyme Care says it uses value-based and risk-bearing contracts with some payer and provider partners.

On its sales page, OncoHealth says it serves health plans and employers with oncology utilization management, prior-authorization support through OneUM, virtual supportive care through Iris and analytics through Oncology Insights. That model places more emphasis on managing treatment decisions and authorization for payers, while Thyme Care wraps between-visit patient support around risk-bearing contracts and provider partnerships.

Lantern says its employer cancer benefit includes oncology-certified nurse navigators, a curated specialist network, ongoing clinical oversight and site-of-care optimization. Thyme Care reaches employers too, but its operating model extends into health-plan contracts and relationships with community oncologists.

Navigating Care, developed by Navigating Cancer, offers oncology practices a patient engagement portal, real-time symptom reporting, oral medication adherence reporting and medication reminders. Daymark Health says its oncology teams support patients by phone, text, video and in the home. Those competitors show how fragmented the category remains: navigation can be sold as software, an employer benefit, a payer cost-control service or a risk-bearing care model.

The scale investors are underwriting

Thyme Care reported that its services are available to more than 10.5 million people across all 50 states, with more than $7 billion in oncology spending under management and a provider network of more than 1,400 oncologists.

Thyme Care also says it is profitable, produces positive free cash flow and reduces total care costs by 5% to 10%. Those outcomes remain company-reported, and the supplied research does not identify an independent validator for the savings range. They remain central to the financing case because Thyme Care assumes financial accountability through value-based arrangements, tying its economics to care quality and spending instead of relying solely on software fees.

The Series E arrives less than a year after Thyme Care raised $97 million at a valuation above $1 billion. The new round values it above $2 billion. Thyme Care's announcement presents the existing navigation and care-management operation as the anchor business for the independent companies Shah and Green plan to develop.

That plan carries execution risk. Navigation, biosimilar adoption and clinical-trial enrollment involve different buyers, regulations and operating teams. Thyme Companies has disclosed its first two areas of work, but it has not named the first business, identified its operating team or explained how the new ventures will be financed after launch.